Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Companyâ€™s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.